Concomitant Use of the 3-Dose Oral Pentavalent Rotavirus Vaccine With a 3-Dose Primary Vaccination Course of a Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Inactivated Polio-Haemophilus influenzae Type b Vaccine
| Autor: | Guanghan F. Liu, Thomas Rose, Florian Schödel, Su He, Maria Petrecz, Max Ciarlet, Sherry Lai, Dieter Y. Koller, Pierre Van Damme, Falko Panzer, Penny M. Heaton, Elena Mikviman, Guojun Yuan |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
Microbiology (medical) animal diseases viruses Dose-Response Relationship Immunologic Antibodies Viral Diphtheria-Tetanus-acellular Pertussis Vaccines medicine.disease_cause complex mixtures Rotavirus Infections Haemophilus influenzae Double-Blind Method medicine Humans Hepatitis B Vaccines Vaccines Combined Bacterial Capsules Whooping cough Haemophilus Vaccines Reactogenicity Tetanus Polyvalent Vaccine business.industry Diphtheria Rotavirus Vaccines Infant virus diseases medicine.disease Antibodies Bacterial Virology Rotavirus vaccine Gastroenteritis Vaccination Poliovirus Vaccine Inactivated Treatment Outcome Infectious Diseases Pediatrics Perinatology and Child Health Immunology Female Human medicine business |
| Zdroj: | The pediatric infectious disease journal |
| ISSN: | 0891-3668 |
| Popis: | Background: The pentavalent rotavirus vaccine (PRV), RotaTeq, can be concomitantly administered with most routine childhood vaccines. This study evaluated the immunogenicity and reactogenicity of PRV when used concomitantly with a hexavalent vaccine containing diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus, and Haemophilus influenzae type b. Methods: Healthy infants (N = 403) received hexavalent vaccine concomitantly with either PRV or placebo at 2, 3, and 4 months of age. Antibody responses were measured immediately before and 42 +/- 3 days after vaccination. Parents/legal guardians recorded all adverse events for 14 days after vaccination. Results: Seroprotective titers for hepatitis B (hepatitis B surface antigen >=10 mIU/mL) were achieved by 97.8% of subjects in both vaccine treatment groups. Seroprotective titers to H. influenzae type b (polyribosylribitol phosphate >=0.15 [mu]g/mL) were achieved by 91.4% of subjects receiving both vaccines and 95.1% of subjects receiving only hexavalent vaccine. Seroprotective titers to diphtheria, tetanus, and poliovirus were also comparable between the vaccine treatment groups, as were geometric mean antibody titers to the pertussis antigens. Among PRV recipients, 92% had a >=3-fold rise in serum antirotavirus immunoglobulin A levels. Concomitant administration was well tolerated. The incidence of adverse events was similar for both groups, with no statistically significant increases in fever, vomiting, diarrhea, or irritability. Conclusions: In this study, concomitant administration of PRV with hexavalent vaccine was well tolerated and the immune responses to the antigens of the hexavalent vaccine were noninferior when compared with those of the control group. In addition, PRV was immunogenic when administered concomitantly with hexavalent vaccine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|